

Special Issue

Molecular Research in Chronic Dermatoses

Message from the Guest Editors

Chronic inflammatory dermatoses are a group of skin disorders characterized by recurrent and debilitating course and destructive influence on patients' life. The pathogenesis of most of them is not fully understood. Therefore, treatment is challenging both for physicians and their patients, and the outcome is often unsatisfactory. In recent years, outstanding progress in understanding the molecular mechanisms behind the pathogenesis of inflammatory dermatoses has been achieved. Studies have led to the development of new therapies, including biologics (chimeric, humanized, and human monoclonal antibodies) and their biosimilars, as well as systemic and topical small molecules (e.g., JAK inhibitors), which have revolutionized the management of patients suffering from chronic inflammatory dermatoses. This Special Issue is now open for submission. Our aim is to publish state-of-the-art articles about the molecular mechanisms in, hidradenitis suppurativa, psoriasis, atopic dermatitis, alopecia areata, vitiligo, and chronic spontaneous urticaria. This Special Issue will accept review articles, original research, and updated information on the pathophysiology and molecular pathways.

Guest Editors

Dr. Piotr K. Krajewski

Department of Dermatology, Venereology and Allergology, Wrocław Medical University, 50-368 Wrocław, Poland

Dr. Antonio Martorell-Calatayud

Department of Dermatology, Hospital Manises, 46940 Valencia, Spain

Deadline for manuscript submissions

closed (30 November 2023)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/135403

*Current Issues in Molecular
Biology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.